Multiple endocrine neoplasia type 2 prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 18: | Line 18: | ||
|} | |} | ||
<br><br><br><br><br><br> | <br><br><br><br><br><br> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 18:54, 28 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 prevention On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Secondary Prevention
Surveillance of multiple endocrine neoplasia type 2 |
---|
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A ) |
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually |
Catacholamines, epinephrine and norepinephrine yearly for multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B patients to detect pheochromocytoma |
Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years |
Parathyroid hormone level yearly for multiple endocrine neoplasia type 2A to detect hypoparathyroidism |